Dabur Pharmaceuticals Ltd, a division of the Rs 915-crore
healthcare major Dabur India Ltd, has set up its maiden overseas venture in Britain with a
$ 5 million investment commitment. It is also considering similar ventures in Russia and
in African countries.
The move is in line with the company''s expansion plans to
enter overseas markets, especially in the area of oncological, or anti-cancer, products.
Dabur''s British arm has been registered as Axol, a
separate company to manufacture and market oncological products for the European markets.
Axol will manufacture and market Dabur''s products sold in India along with products
developed exclusively for the European markets.
"We have already obtained permission from the British
government to invest $5 million including a manufacturing unit, which will be fully
operational in the next couple of years," says Suresh Pathak, general manager -
marketing and sales - Dabur Pharmaceuticals Ltd.
Commenting on the company''s domestic plans, Mr Pathak said
the company would introduce six new products, two each in therapeutic segments of
gynaecology, oncology and respiratory, over the next 12 months. The gynaecological product
Nefralein Nasal spray to treat endometriosis will be launched in September 1999. The
products have been developed by Dabur Research Foundation.
Dabur Pharmaceuticals markets products in
the therapeutic segments of oncology,
radiology, gastrointestinal, gynaecology and anti-infectives. Oncology is the leading
segment, accounting for 25 per cent of the company''s turnover. The company is aiming for
Rs 100-crore sales by the end of the 1999-2000 financial year against Rs 72-crore in